D-0633-2024 Class III

Recalled by Taro Pharmaceuticals U.S.A., Inc. — Hawthorne, NY

FDA drug recall D-0633-2024 was initiated by Taro Pharmaceuticals U.S.A., Inc. on Aug 7, 2024 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: Out-of-specification results obtained for related impurities and slightly lower than the established level of the Hydrocortisone Assay obtained during… Affected quantity: 96 vials.

Recall details

Product Type
Drugs
Report Date
Aug 21, 2024
Initiation Date
Aug 7, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
96 vials

Product description

Hydrocortisone 1% & Acetic Acid 2% Otic Solution, 10 mL bottle, Rx only, Mfg by: Taro Pharmaceuticals, Inc., Brampton, Ontario, Canada L6T 1C1, Distributed by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532, NDC 51672-3007-01

Reason for recall

Failed Impurities/Degradation Specifications: Out-of-specification results obtained for related impurities and slightly lower than the established level of the Hydrocortisone Assay obtained during stability testing.

Distribution pattern

Product was distributed to one distributor

Code information

Lot # AD12890, Exp 09/30/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0633-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0633-2024. Report a data issue: hello@regdatalab.com.